i-Lumen Scientific begins U.S. pivotal trial of microcurrent therapy for dry AMD
i-Lumen Scientific, Inc. has randomized the first United States patient in its pivotal i-SIGHT2 study, beginning the domestic phase of a multinational trial evaluating whether low-level electrical stimulation delivered through a closed eyelid can improve visual function in people with intermediate-to-advanced dry age-related macular degeneration. The first U.S. randomization occurred at Texas Retina Associates in
